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Abstract
Introduction The tumour-suppressive effects of transforming
growth factor-beta (TGF-β) are well documented; however, the
mechanistic basis of these effects is not fully understood.
Previously, we showed that a non-canonical member of the
Wingless-related protein family, Wnt5a, is required for TGF-β-
mediated effects on mammary development. Several lines of
evidence support the hypothesis that Wnt5a acts as a tumour
suppressor. In addition, it has been shown that Wnt5a can
antagonise canonical Wnt/β-catenin signalling in various cell
types. Here we test the hypothesis that TGF-β and Wnt5a can
antagonise Wnt/β-catenin signalling and redirect mammary
tumour phenotype. The results provide a new mechanism for the
tumour-suppressive effects of TGF-β.
Methods Wnt/β-catenin signalling was measured in tumours
with altered TGF-β (dominant-negative TGF-β type II receptor,
DNIIR) or Wnt5a (Wnt5a-/-) signalling as the accumulation of
nuclear  β-catenin using both confocal microscopy and cell
fractionation. RT-PCR was used to measure the expression of
Wnt/β-catenin target genes. Sca1 expression was determined
by western blot and keratin (K) 6- and K14-positive populations
were determined by immunohistochemistry.
Results Loss of TGF-β or Wnt5a signalling resulted in
stabilisation of nuclear β-catenin and expression of Wnt/β-
catenin target genes suggesting that TGF-β and Wnt5a act to
inhibit Wnt/β-catenin signalling in mammary epithelium.
Increased expression of Sca-1 was observed in developing
DNIIR and Wnt5a-/- mammary glands. DNIIR and Wnt5a-/-
tumours demonstrated an expanded population of K6- and K14-
expressing cells typically seen in Wnt/β-catenin-induced
tumours.
Conclusions The key findings here are that: TGF-β and Wnt5a
regulate Wnt/β-catenin activity; and loss of TGF-β and Wnt5a
redirect the phenotype of tumours so that they resemble
tumours induced by activation of Wnt/β-catenin. The findings
suggest a new mechanism for the tumour-suppressive effects of
TGF-β.
Introduction
Transforming growth factor-β (TGF-β) is responsible for the
maintenance of homeostasis in many epithelial tissues that
exhibit a high rate of cell turnover. Consequently, disruption of
TGF-β signalling is attributed to the development of human
carcinomas including colon, gastric and breast cancers [1,2].
Ligand binding to the type II TGF-β receptor (TGF-βRII)
recruits and activates the type I TGF-β receptor (TGF-βRI) via
serine/threonine phosphorylation, thereby activating down-
stream Smad signal transducers. Although mutations in genes
encoding proteins in the TGF-β signalling pathway are uncom-
mon in human breast cancers, loss or diminished expression
of TGF-βRII confers a 3.4-fold greater risk of developing inva-
sive breast carcinoma in a subset of patients [3] and is asso-
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ciated with higher histological grade in human breast in situ
and invasive carcinomas [4]. Moreover, using both gain- and
loss-of-function approaches, a variety of transgenic mouse
models support a tumour-suppressive role for TGF-β in mam-
mary cancers (reviewed in [2]). For example, overexpression of
TGF-β1 in the mammary epithelium via MMTV-TGF-β1 or
WAP-TGF-β1 inhibits the formation of TGF-α and 7, 12-
dimethybenz(a)anthracene (DMBA)-induced tumours. In con-
trast, interruption of endogenous TGF-β signalling via overex-
pression of a dominant-negative TGF-βRII mutant (DNIIR) or
Cre/Lox deletion of Tgfbr2 within the mammary epithelium
increases tumour incidence. Recently, we identified a non-
canonical member of the Wingless-related protein family,
Wnt5a, as a downstream target for TGF-β in mammary gland
development [5].
Like the TGF-β family of polypeptides, Wnt proteins make up
a large family of essential signalling molecules that mediate a
range of cellular behaviours including cell fate specification,
cell polarity and cell migration [6]. Moreover, mutations or
alterations in the Wnt pathway contribute to a variety of human
cancers, the majority of which exhibit deregulated intracellular
β-catenin levels and, thus, increased β-catenin activity. Evi-
dence suggests the Wnt/β-catenin pathway preferentially
induces mammary cancers from progenitor cells, with tumours
exhibiting expansion of undifferentiated keratin (K) 6 and Sca-
1-positive populations, along with both luminal and uncharac-
teristic myoepithelial lineages throughout the tumours.
Although most studies have focused on the Wnt/β-catenin
pathway, other Wnt signalling pathways exist that signal inde-
pendently of β-catenin, so-called non-canonical pathways.
Interestingly, studies suggest that Wnt5a, a non-canonical sig-
nalling Wnt, can antagonise the Wnt/β-catenin pathway; how-
ever, the mechanism and biological consequences of this
antagonism vary by tissue type [7-10].
Several lines of evidence support the hypothesis that Wnt5a
acts as a tumour suppressor. Overexpression of Wnt5a is able
to partially revert the transformed phenotype of C57MG cells
in vitro after ectopic expression of Wnt1, while anti-sense sup-
pression of Wnt5a expression causes a similar cell morphol-
ogy exhibited by Wnt1-transformed C57MG cells [11]. Loss
of Wnt-5a protein expression in invasive ductal carcinomas
also correlates with an increased risk of early relapse and mor-
tality for patients [12,13]. Additionally, Wnt5a mRNA levels
seem to decline with more advanced stages of breast disease
[13]. In light of solid credentials in favour of Wnt5a as a tumour
suppressor, other studies present evidence for an oncogenic
role for Wnt5a [14,15]. It is likely that the tumour-suppressive
and oncogenic effects of Wnt5a are highly dependent on the
cell type and context in which the signalling occurs; however,
these discrepancies clearly emphasise the need for further
investigation.
Here, we show that dominant-negative interference of TGF-β
signalling in tumours results in reduced Wnt5a expression.
Next, we showed that expression of DNIIR or loss of Wnt5a in
mammary tissue enhances Wnt/β-catenin activity. In addition,
loss of TGF-β or Wnt5a signalling results in increased Sca1
expression and redirection of tumour phenotype to that con-
sistent with excess Wnt/β-catenin signalling, including an
increase in K6- and K14-positive cell populations. We pro-
pose that Wnt5a acts to mediate some of the tumour-suppres-
sive effects of TGF-β by antagonising the Wnt/β-catenin
pathway.
Materials and methods
Mice
All mice in this study were maintained under the guidelines of
the Institutional Animal Care and Use Committee of the Univer-
sity of Alabama at Birmingham. DNIIR mice were previously
described [16,17]. Wnt5a  disrupted mice (Wnt5atm1/Amc)
were acquired from Jackson Laboratories (Bar Harbor, Maine,
USA) and backcrossed at least five times into a C57Bl/6
background before generating Wnt5a-/- embryos. ICR/SCID
mice were obtained from Taconic Farms (Hudson, NY, USA).
MMTV-PyVmT strains were acquired from Jackson Laborato-
ries and were also backcrossed to a C57BL/6J background.
MMTV-neu mice (FVB) were crossed with hemizygous DNIIR
(C57BL/6) mice to obtain F1 generation MMTV-neu and
MMTV-neu:DNIIR groups. MMTV-PyVmT male mice were
crossed to hemizygous DNIIR females to obtain MMTV-PyVmT
and MMTV-PyVmT:DNIIR groups.
Generation of Wnt5a-/- and PyVmT:Wnt5a-/- epithelium
Rescue of Wnt5a-/- epithelium has been previously described
[5]. PyVmT:Wnt5a-/- epithelium was generated by crossing
MMTV-PyVmT males with Wnt5a+/- females to acquire
MMTV- PyVmT:Wnt5a+/- males that were then bred with
Wnt5a+/- females to yield MMTV-PyVmT and PyVmT:Wnt5a-
/- embryos. Mammary anlagen were then microdissected from
e18.5 day embryos. The buds were pooled and cultured over-
night to form one transplantable unit that was then implanted
the next day into the cleared fat pads of three-week-old ICR/
SCID hosts [18]. During culture of the mammary anlagen over-
night, Wnt5a-/- embryos were screened for the PyVmT trans-
gene. Rescued epithelium was expanded within the fat pad of
ICR/SCID hosts for one month before being removed and
transplanted into cleared host fat pads for experiments.
Generation of organoid preparations for injection into 
fat pad
For PyVmT:DNIIR studies, organoid preparations were pre-
pared from control and experimental groups at three weeks of
age to obtain a homogeneous population of cells for injection
into the cleared mammary fat pads of ICR/SCID hosts. For
PyVmT:Wnt5a-/- studies, organoid preparations were pre-
pared from rescued mammary epithelium that was expanded
within the fat pad. Glands from MMTV-PyVmT and MMTV-Available online http://breast-cancer-research.com/content/11/2/R19
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PyVmT:DNIIR groups, in addition to rescued MMTV-PyVmT
and MMTV-PyVmT:Wnt5a-/- tissue, were minced and enzy-
matically dissociated in 10 ml digestion media/1 g of tissue
(digestion medium: 1 mg/ml type I collagenase and 0.1 mg/ml
pronase in Dulbecco's modified eagle's medium (DMEM)/
F12) for one hour at 37°C at 125 rpm on a rotary shaker. Sam-
ples were pipetted every 20 minutes to expedite dissociation.
Organoids were obtained by differential centrifugation,
washed three times in 1 × PBS, and resuspended in DMEM/
F12. A 50 μl volume of 50 organoids in 1 × Hanks' balanced
salt solution (HBSS) was injected into each fat pad. Isolation
of organoid preparations was consistent between control and
experimental groups, and although organoid sizes vary, this
variability appeared consistent by microscopic visualisation of
the organoids before injection. Successful delivery of organoid
suspensions was confirmed by visible engorgement of the fat
pad upon injection [19].
Tissue processing and immunohistochemistry
Tissues were fixed in 4% paraformaldehyde overnight at 4°C
and processed to paraffin block after graded ethanol dehydra-
tion steps and clearance in xylene. Sodium citrate (10 mM, pH
6) antigen retrieval was used in all immunohistochemistry and
immunofluorescence procedures. Immunohistochemistry was
carried out using the Vector ABC kit (Vector Laboratories,
Burlingame, CA, USA) at the manufacturer's recommenda-
tions. For immunofluorescence, sections were probed with
biotinylated secondary antibodies (1:250; Vector Laborato-
ries) followed by Cy-3 conjugated streptavidin (1:1000;
Zymed Laboratories, San Francisco, CA, USA; 43-4315).
BrdU and TUNEL (terminal deoxynucleotidyl transferase dUTP
nick end labeling) staining have been described previously [5].
Primary antibodies included anti-β-catenin (1:500; Cell Sign-
aling Technologies, Danvers, MA, USA; #9562), anti-keratin-6
(1:500; Covance, Princeton, NJ, USA), anti-keratin-14
(1:1000; Covance; PRB-155P) and anti-CD31 (1:200; Neo-
Markers, Freemont, CA, USA; RB-10333-P0).
Images of the H&E-stained tumours, as well as all of the Ki67,
Brdu, CD31, K14 and K6 stained tissues, were taken using
the 40× objective on an Olympus BX50 microscope (Olym-
pus, Center Valley, PA, USA), a magnafire camera (Olympus)
and PictureFrame software (Olympus). All images were
opened, colours merged and adjusted for sharpness in Adobe
Photoshop (Adobe, San Jose, CA, USA). Confocal image
were taken using the 100× oil objective on a Nikon Eclipse
TE2000-U microscope with a Perkin Elmer Ultra View spin-
ning disc set-up and an EMCCD C9100-50 camera using
Ultraview ERS acquisition software (Ultraview, Waltham, MA,
USA). Figures were composed using Adobe Photoshop.
Isolation and treatment of mammary epithelial cells with 
recombinant Wnt proteins
Adult virgin Balb/c mice (8 to 10 weeks of age) were the
source of primary mammary epithelial cells. Cell fractions were
isolated by enzymatic dissociation and Percoll gradient den-
sity centrifugation as previously described [20]. Fibroblasts
were plated in DMEM/F12 supplemented with 5% fetal bovine
serum (FBS), 100 μg/ml penicillin and 50 μg/ml streptomycin,
were allowed to attach for two hours, were rinsed with 1 ×
PBS and were refreshed with growth medium. The epithelial
cells were plated 1 × 105 cells/cm2 in DMEM/F12 supple-
mented with 5% FBS, 20 ng/ml epidermal growth factor
(EGF), 0.5 μg/ml hydrocortisone, 100 ng/ml cholera toxin, 10
μg/ml insulin, 100 μg/ml penicillin and 5 μg/ml streptomycin
(Clonetech, Mountain View, CA, USA). Cultures were allowed
to grow until 70% confluent, and then serum starved overnight
in basal medium (DMEM/F12 supplemented with 0.1 mM non-
essential amino acids, 0.1 μg/ml insulin, 1 mg/ml fatty acid-
free BSA (fraction V), 100 μg/ml penicillin and 50 μg/ml strep-
tomycin) (Clonetech) prior to treatment with recombinant Wnt
proteins. rWnt5a and rWnt3a were purchased from R&D sys-
tems (Minneapolis, MN, USA) (rmWnt5a cat# 645-WN-010
and rmWnt3a cat# 1324-WN-002).
Mammary gland and tumour subcellular fractionation 
and western blotting
Single cell suspensions of mammary glands and tumours were
obtained before subcellular fractionation procedures. Glands
and tumours were minced and enzymatically dissociated in 10
ml digestion media/1 g tissue (see organoid preparation sec-
tion) to arrive at an organoid preparation. The pelleted orga-
noids were resuspended in 2 ml trypsin-EDTA (1 mM EDTA-
4NA, 2.5 g/L porcine trypsin, in HBSS, Ca++ Mg++ free), and
pipetted up and down for one minute before adding 8 ml mod-
ified HBSS (with 10 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES)) supplemented with 2%
FBS. This suspension was centrifuged at 350 × g for five min-
utes. The organoids were further dissociated in a Dispase/
DnaseI solution (2 ml of 5 mg/ml Dispase + 200 μl 1 mg/ml
DnaseI; Invitrogen, Carlsbad, CA, USA), resuspended in mod-
ified HBSS, filtered through a 40 μm filter, and washed three
times in 1 × PBS. After washing, the pellet of single mammary
and tumour cells was fractionated into cytosolic and nuclear
compartments, as previously described [21]. Protein lysate
from cell fractions was resolved on an 8% SDS-PAGE gel,
transferred to polyvinylidene fluoride membrane and probed
with the indicated antibodies anti-β-catenin (1:1000, Cell Sig-
naling Technologies), anti-Sca1, (1:1000, R&D systems;
#AF1226), anti-Creb (1:1000; AbCam, Cambridge, MA,
USA), anti-β-tubulin (1:1000; Santa Cruz, Santa Cruz, CA,
USA) according to standard protocols.
RNA Isolation and semi-quantitative RT-PCR
RNA isolation was performed using Trizol® reagent according
to the manufacturer's instructions. Relative levels of mRNAsBreast Cancer Research    Vol 11 No 2    Roarty et al.
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were determined using semi-quantitative RT-PCR. cDNA was
synthesised from 5 μg total RNA using random primers. cDNA
was then amplified using specific primers as follows: 18Sfwd
5'-ACGGAAGGGCACCACCAGG-3', 18Srev 5'-CAC-
CAACTAAGAACGGCCATGC-3', tcf-4fwd 5'-ATGGCCAT-
CACAGCAGCGAC-3', tcf-4rev 5'-
CTGTCTGTTCCGTTGGCAGGG-3', c-mycfwd 5'-CGAT-
GCCCCTCAACGTGAAC-3', c-mycrev 5'-CAGGCTGGT-
GCTGTCTTTGC-3', cyclin D1 F 5'-
GTCTGTGAGGAGCAGAAGTGC-3', cyclinD1 R 5'-
GGCCGGATAGAGTTGTCTGTG-3', axin2F 5'-GAG-
TAGCGCCGTGTTAGTGACT-3', axin2R 5'-CCAG-
GAAAGTCCGGAAGAGGTATG-3', Sca1fwd 5'-
GCCCATCAATTACCTGCCC-3', Sca1rev 5'-CCT-
GGCAACAGGAAGTCTTG-3'. Amplification of cDNA was
performed over varying cycles to arrive at product formation in
the linear range.
Statistical methods
The length and width of the tumours were measured with a cal-
iper. Tumour volume was calculated by the formula: volume =
(width2 × length)/2. The analysis of subcutaneous MMTV-neu
tumour volume was performed using a repeated measures
model with PROC MIXED (SAS Version 9.1, Cary, NC, USA).
The a priori planned comparisons of specific differences in
predicted treatment means at 63 days were computed by t-
statistics (Student's t-test). For all analyses a two-sided p
value of less than 0.05 was deemed statistically significant.
For other tumour volume measurements, proliferation and
CD31 vessel density, mean values were calculated then sta-
tistical significance was evaluated based on t-statistics and
plots were generated using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, CA, USA).
Results
Interruption of TGF-β signalling enhances tumour 
growth accompanied by diminished Wnt5a protein levels
Previously, we showed that expression of Wnt5a is positively
regulated by TGF-β, mimicks the inhibitory effects of TGF-β
during mammary development and is required for TGF-β-medi-
ated inhibition of branching in vivo and in vitro [5]. To deter-
mine the effects of alterations in TGF-β signalling (DNIIR) on
Wnt5a expression during mammary tumour progression we
used the previously characterised MMTV-neu [22] and MMTV-
PyVmT [23] models of mouse mammary tumourigenesis. Dom-
inant-negative interference of TGF-β signalling was achieved
by crossing MMTV-neu or MMTV-PyVmT mice with the MT-
DNIIR model that has been previously described [17]. MMTV-
neu;DNIIR tumours were spontaneous tumours generated in
the F1 generation of MMTV-neu and DNIIR crosses. In the
MMTV-PyVmT study, tumours were generated by transplant-
ing organoids isolated from MMTV-PyVmT or MMTV-
PyVmT;DNIIR mammary glands into Scid hosts. Time of
tumour detection was denoted by the presence of a palpable
2 × 2 mm mass within the fat pad. For the MMTVneu study,
mice were sacrificed when the tumour volume reached 2 cm
or if the mice became moribund. The study ended at 14
months and all remaining mice were sacrificed. MMTV-PyVmT
tumours arise much more quickly, so all the mice on the
MMTV-PyVmT;DNIIR study were sacrificed at 10 weeks (70
days). All tumours generated here were classified as invasive
adenocarcinomas.
Repeated measures modelling was used to extrapolate
tumour volume at 63 days post-detection for MMTV-neu and
MMTV-neu;DNIIR tumours. The results indicated significantly
faster growth and larger tumours in the MMTV-neu:DNIIR
group compared with the control MMTV-neu (Figure 1a). Like-
wise, MMTV-PyVmT:DNIIR tumours were larger at the time of
sacrifice (70 days) compared with control MMTV-PyVmT
tumours (Figure 1b). In both models, overexpression of DNIIR
increased proliferation rates in the primary tumours, illustrated
by Ki67 staining or BrdU incorporation (Figures 1c, d). No sta-
tistical differences in apoptosis were observed in tumours har-
boring intact versus altered TGF-β signalling (data not shown).
We also identified differences in microvessel density between
control and DNIIR groups. In both MMTV-neu and MMTV-
PyVmT models, overexpression of DNIIR resulted in an
increase in the extent of vasculature throughout the primary
tumours, depicted by CD31 immunostaining (Figures 1e, f).
By western blotting, Wnt5a protein levels were reduced in
tumours with altered TGF-β responsiveness in both the
MMTV-neu (Figure 1g) and MMTV PyVmT (Figure 1h) models
suggesting that, in addition to regulating Wnt5a in normal
mammary development, TGF-β can act to maintain Wnt5a
expression during tumour formation.
Absence of Wnt5a promotes tumour growth and 
accumulation of β-catenin
To address the role of Wnt5a in mammary tumour formation,
we derived MMTV-PyVmT and MMTV-PyVmT: Wnt5a-/- epi-
thelium by rescue of embryonic mammary anlagen as previ-
ously described [5]. After 16 weeks, tumours in each group
were classified as invasive adenocarcinomas. Histological
evaluation of the tumours by H&E staining revealed the pres-
ence of pleomorphic nuclei with high nuclear to cytoplasmic
ratios in MMTV-PyVmT:Wnt5a-/- tumours when compared
with control MMTV-PyVmT tumours (Figure 2a). In the
absence of Wnt5a, tumour volume was approximately two-fold
greater than control MMTV-PyVmT tumours at the time of sac-
rifice (Figure 2b). By Ki67 staining, PyVmT:Wnt5a-/- epithe-
lium exhibited a significant increase in proliferation compared
with controls (Figure 2c). Together, the data demonstrate that
alterations in TGF-β signalling or loss of Wnt5a  enhance
tumour growth.Available online http://breast-cancer-research.com/content/11/2/R19
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Since others have observed high nuclear to cytoplasmic ratios
and pleomorphic nuclei associated with Wnt1-induced
tumours [24] and it has been suggested that Wnt5a can
antagonise the Wnt/β-catenin pathway [7-10], we tested the
hypothesis that Wnt5a is a negative regulator of the Wnt/β-
catenin pathway in the mammary gland. To determine if Wnt5a
could antagonise the Wnt/β-catenin pathway in mammary epi-
thelium, primary cells in culture were treated with a recom-
binant canonical signalling Wnt, rWnt3a, alone or with rWnt3a
and rWnt5a in combination. After overnight treatments,
rWnt3a increased the levels of nuclear β-catenin, while
rWnt5a was able to suppress rWnt3a-induced nuclear β-cat-
enin levels (Figure 3a). The results suggested that primary
mammary epithelium is capable of responding to canonical
Wnt and that Wnt5a can antagonise this response.
Next, we investigated β-catenin levels in Wnt5a-/- and wild
type (WT) mammary epithelium, three weeks post-transplanta-
tion. During adolescence, TOPGAL (Wnt responsive β-galac-
tosidase activity) activity, a measure of canonical Wnt/β-
catenin signalling in the mammary gland, is very low to unde-
tectable [25], so we reasoned that if there were changes in
intracellular β-catenin due to loss of Wnt5a, they should be
detectable at this stage. Little to no β-catenin was detected by
confocal microscopy in the cytoplasm or nucleus of sections
from WT glands. Interestingly, Wnt5a-/- epithelium exhibited
increased levels of intracellular β-catenin compared with WT
(Figure 3b). Furthermore, subcellular fractionation and protein
isolation from WT and Wnt5a-/- epithelium followed by west-
ern blot analysis demonstrated an increase in the accumula-
tion of nuclear β-catenin in the absence of Wnt5a (Figure 3c).
Figure 1
Wnt5a protein levels are reduced in DNIIR tumours Wnt5a protein levels are reduced in DNIIR tumours. (a) Repeated measures modelling of tumour volume over time in the MMTV-neu model shows 
statistically significant differences at 63 days in mean tumour volume between control and DNIIR groups (P < 0.01; control = 2.57 cm3 ± 0.53 cm3, 
n = 12; DNIIR = 4.21 cm3 ± 0.17 cm3, n = 33). (b) In the MMTV-PyVmT model, a graphical plot of mean tumour volumes at the time of sacrifice 
reveals significantly larger tumours in the DNIIR group versus controls (P < 0.0001; control = 20 mm3, n = 8; DNIIR = 65 mm3, n = 8). (c) Ki67 
staining in the MMTVneu model shows increased levels of proliferation in the DNIIR primary tumours compared with controls (P < 0.0001; six 
tumours per group, five fields per tumour were counted). (d) BrdU incorporation in tumours of the MMTV-PyVmT study illustrates increased prolifer-
ation in DNIIR tumours (P < 0.0001; eight tumours per group, three fields per tumour). (e, f) Vascular density, measured by CD31 pixel density, was 
greater in DNIIR groups within both (e) MMTV-neu and (f) MMTV-PyVmT studies (MMTV-neu = P <0.02, five tumours per group, three fields per 
tumour; MMTV-PyVmT = P < 0.01, four tumours per group, three fields per tumour). (g, h) Western blotting for Wnt5a protein in lysates from several 
separate (g) MMTV-neu and (h) MMTV-PyVmT tumours with or without DNIIR, indicating a decrease in overall levels of Wnt5a protein in primary 
tumours with alterations in TGF-β signalling. β-Tubulin is used as a loading control. DNIIR = dominant-negative TGF-β type II receptor; MMTV = 
mouse mammary tumour virus promoter/enhancer; PyVmT = polyoma virus middle T antigen; TGF-β = τransforming growth factor-beta; Wnt = 
Wingless-related protein family.Breast Cancer Research    Vol 11 No 2    Roarty et al.
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The results suggested that Wnt5a normally acts to inhibit the
stabilisation β-catenin in the developing mammary gland.
To determine if loss of Wnt5a also affected stabilisation of β-
catenin in MMTV-PyVmT tumours, we analysed MMTV-PyVmT
and MMTV-PyVmT:Wnt5a-/- tumours for differences in β-cat-
enin levels. Immunostaining and confocal microscopy on sec-
tions from control and Wnt5a-/- tumours revealed elevated
levels of intracellular β-catenin in the absence of Wnt5a (Fig-
ure 3d). Control MMTV-PyVmT tumours exhibited predomi-
nantly membrane-associated β-catenin. Moreover, subcellular
fractionation and western blotting showed an increase in β-
catenin in the nuclear compartment of cells in the Wnt5a-/-
tumours (Figure 3e). Analysis of Wnt/β-catenin target genes
such as c-myc [26], tfc4 [27] and axin 2 (Figure 3f) by RT-PCR
indicated that the transcriptional activity of the Wnt/β-catenin
pathway was enhanced in the absence of Wnt5a. Cyclin D1
was only modestly regulated. Thus, the data suggest that loss
of Wnt5a results in increased canonical Wnt/β-catenin signal-
ing in MMTV-PyVmT tumours.
Accumulation of intracellular β-catenin occurs in 
tumours with dominant-negative interference of TGF-β 
signalling
Upon determining that Wnt5a limits the accumulation of intra-
cellular β-catenin in normal mammary epithelium and tumours,
we speculated that tumours harboring DNIIR would also
exhibit stabilised intracellular β-catenin, probably as a conse-
quence of reduced Wnt5a levels. To confirm this, MMTV-
PyVmT tumours with intact or altered TGF-β signalling were
immunostained for β-catenin. The accumulation of intracellular
of  β-catenin was apparent by confocal microscopy in the
DNIIR tumours relative to control tumours where the majority
of β-catenin was membrane-associated (Figure 3g). This pat-
tern was observed in MMTV-Neu;DNIIR tumours as well as in
the developing DNIIR mammary gland (data not shown). More-
over, subcellular fractionation of the cells in PyVmT tumours
revealed elevated levels of nuclear β-catenin in DNIIR tumours
compared with the control group (Figure 3h). The results sug-
gest that loss of responsiveness to TGF-β also results in an
increase in Wnt/β-catenin signalling in mammary tumours.
DNIIR and Wnt5a-null tissue demonstrate an increase in 
Sca1, K6 and K14 expression
We originally identified Wnt5a as a target of TGF-β action in a
microarray screen comparing WT and DNIIR mammary glands
[5]. In addition to alterations in expression of Wnt5a, up-regu-
lation of Sca1 was detected in this original microarray screen
(data not shown). Interestingly, MMTV-Wnt1 mice also dem-
onstrate increased Sca1 expression in the mammary gland
[28,29]. To confirm the results seen in the microarray, regula-
tion of Sca1 mRNA was compared in WT and DNIIR glands
using RT-PCR (Figure 4a). Sca1 mRNA was clearly up-regu-
lated in the mammary glands of two separate DNIIR mice when
Figure 2
Absence of Wnt5a enhances growth of MMTV-PyVmT tumours Absence of Wnt5a enhances growth of MMTV-PyVmT tumours. (a) Representative bright field images of H&E-stained MMTV-PyVmT and MMTV-
PyVmT:Wnt5a-/- tumours. Arrows denote the large pleomorphic nuclei in Wnt5a-/- tumours. (b) Tumour volume at the time of sacrifice. Tumour vol-
ume is significantly larger in the absence of Wnt5a (eight per group, PyVmT mean tumour volume 0.46 cm3, PyVmT:Wnt5a-/- mean tumour volume 
1.1 cm3; P < 0.0001). (c) Proliferation of MMTV-PyVmT:Wnt5a-/- and control MMTV-PyVmT tumours. Ki67 staining illustrates a significant increase 
in proliferation in the absence of Wnt5a (P < 0.0001, eight MMTV-PyVmT:Wnt5a-/- sections, three fields per section; four MMTV:PyVmT sections, 
three fields per section). DNIIR = dominant-negative transforming growth factor-β type II receptor; H&E = haematoxylin and eosin; MMTV = mouse 
mammary tumour virus promoter/enhancer; PyVmT = polyoma virus middle T antigen; Wnt = Wingless-related protein family.Available online http://breast-cancer-research.com/content/11/2/R19
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Figure 3
TGF-β and Wnt5a can inhibit the Wnt/β-catenin pathway TGF-β and Wnt5a can inhibit the Wnt/β-catenin pathway. (a) Western blot of β-catenin protein from fractionated primary mammary epithelial cells 
after overnight stimulation with 60 ng/ml rWnt3a alone or in combination with 80 ng/ml rWnt5a. rWnt3a elevated nuclear β-catenin levels in epithe-
lial cells, while rWnt5a inhibited rWnt3a-induced levels. (b) Immunofluorescent staining and confocal imaging for β-catenin in sections of WT and 
Wnt5a-/- mammary epithelium after three weeks of development illustrating nuclear and cytoplasmic localisation of β-catenin in Wnt5a-/- epithelium. 
A representative of five separate glands is shown. (c) Western blot shows the accumulation of β-catenin in the nuclear compartment of Wnt5a-/- 
epithelium relative to WT epithelium. (d) β-catenin localisation in MMTV-PyVmT and MMTV-PyVmT:Wnt5a-/- tumours (five tumours per group). The 
arrows point to examples of nuclei. (e) Subcellular fractionation and western blotting for β-catenin protein show elevated β-catenin levels in the 
nucleus of cells from Wnt5a-/- tumours. (f) Semi-quantitative RT-PCR using cDNA generated from individual MMTV-PyVmT and MMTV-
PyVmT:Wnt5a-/- tumours, exhibiting increased Wnt/β-catenin transcriptional responses in the absence of Wnt5a (four control tumours, five Wnt5a-
/- tumours). 18S was used to normalise for the amount of total RNA. PCR product is shown in the linear range (25 cycles for axin, tcf4, cyclin D1 and 
c-myc, and 15 cycles for 18S). (g) Immunofluorescent staining and confocal imaging (representative of four tumours per group), and (h) represent-
ative western blot of proteins from fractionated tumours, together, illustrating an increase in intracellular β-catenin when TGF-β signalling is blocked 
via overexpression of DNIIR. Arrows point to examples of nuclei. CREB is used as a loading control for the nuclear fraction, β-Tubulin is used as a 
loading control for the cytoplasmic fraction. DNIIR = dominant-negative TGF-β type II receptor; H&E = haematoxylin and eosin; MMTV = mouse 
mammary tumour virus promoter/enhancer; PyVmT = polyoma virus middle T antigen; RT-PCR = reverse transcripase polymerase chain reaction; 
TGF-β = transforming growth factor-beta; Wnt = Wingless-related protein family; WT = wild type, CREB+ c-AMO response element binding factor.Breast Cancer Research    Vol 11 No 2    Roarty et al.
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compared with controls. To determine if Sca1 protein was also
up-regulated, we used western blot analysis (Figure 4b). The
levels of Sca1 protein were increased in DNIIR glands com-
pared with controls.
To determine if loss of Wnt5a also resulted in an increase in
Sca1 expression, we compared Sca1 protein levels in tissue
rescued from three separate WT and Wnt5a-/- mice by west-
ern blot (Figure 4c). Loss of Wnt5a also resulted in a signifi-
cant increase in Sca1 protein levels in the mammary gland
relative to WT controls.
We next tested the hypothesis that the absence of Wnt5a or
TGF-β signalling would redirect the phenotype of MMTV-
PyVmT tumours to a phenotype consistent with activated Wnt/
β-catenin signalling. A previous study demonstrated the
expansion of a K6 expressing population of cells in tumours
that are induced by components of the Wnt/β-catenin signal-
ling pathway, including Wnt1, c-Myc and β-catenin, yet not in
tumours induced by other oncogenes such as neu, PyVmT and
Ras [29]. Although this K6 population was not observed in
MMTV-PyVmT tumours, we speculated that because MMTV-
PyVmT:Wnt5a-/- tumours display higher levels of intracellular
β-catenin and Wnt5a-/- tissue demonstrates increased
expression of Sca1, an expansion of this K6-positive popula-
tion might exist. Using immunohistochemistry we detected the
presence of a K6 population of cells in PyVmT tumours in the
absence of Wnt5a (Figure 5a), suggesting an expansion of
this population in the tumours. Interestingly, PyVmT tumours
expressing DNIIR also displayed an increase in the K6
expressing population (Figure 5b).
Li and colleagues [29] also established the existence of an
expanded myoepithelial lineage in tumours induced by exces-
sive canonical Wnt signalling. The expansion of this myoepi-
thelial lineage was not observed in tumours transformed by
oncogenes such as PyVmT. MMTV-PyVmT tumours, in the
absence of Wnt5a also contained an expanded myoepithelial
lineage, marked by K14 (Figure 5c). The myoepithelial lineage
seemed to mimic what was observed in Wnt/β-catenin-
induced tumours, with enlarged and rounded morphology
[29]. MMTV-PyVmT:DNIIR tumours also contained this unu-
sual K14 positive population (Figure 5d). These results sug-
gest that alterations in TGF-β signalling and deletion of Wnt5a
promote the expansion of a myoepithelial lineage typically
observed in canonical Wnt-induced tumours. Together the
results suggest that loss of TGF-β or Wnt5a can redirect the
phenotype of MMTVPyVmT tumours to a phenotype consist-
ent with activated Wnt/β-catenin.
Discussion
In this study, we present evidence to support a model in which
TGF-β and a non-canonical signalling Wnt, Wnt5a, act as
antagonists of the Wnt/β-catenin pathway in the mammary
gland. Furthermore, DNIIR and Wnt5a-/- tumours show simi-
larities to tumours induced by activation of Wnt/β-catenin in
their ability to expand a K6 progenitor cell population in addi-
tion to a unique K14 expressing population. Specifically, we
propose that TGF-β inhibits Wnt/β-catenin signalling through
the regulation of Wnt5a expression and that alteration in TGF-
β signalling via dominant-negative interference or Wnt5a sig-
nalling, using Wnt5a-/- mammary tissue, promote the stability
of intracellular β-catenin and redirect the formation of tumours
to a Wnt/β-catenin phenotype.
Several lines of evidence support a model in which TGF-β sig-
nalling has opposing effects on Wnt/β-catenin signalling in the
Figure 4
Sca1, a marker of mammary stem/progenitor cells, is increased in  DNIIR and Wnt5a-/- glands Sca1, a marker of mammary stem/progenitor cells, is increased in 
DNIIR and Wnt5a-/- glands. mRNA and protein were extracted from 
several wild type (WT) and MT-DNIIR (DNIIR) mice. (a) Sca1 mRNA 
levels were determined by semi-quantitative RT-PCR and (b) protein 
levels were determined by western blot. Sca1 levels were increased in 
DNIIR glands relative to controls. (c) Sca1 protein levels were deter-
mined in WT and Wnt5a null (-/-) glands using western blot analysis. 
Sca1 levels were increased in Wnt5a-null tissue relative to controls. 
18S and β-Tubulin (β-Tub) were used as normalisation controls. DNIIR 
= dominant-negative transforming growth factor-β type II receptor; RT-
PCR = reverse transcripase polymerase chain reaction; Wnt = Wing-
less-related protein family.Available online http://breast-cancer-research.com/content/11/2/R19
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mammary gland. Transgenic mice that overexpress a constitu-
tively active form of β-catenin, ΔN89β, under the MMTV pro-
moter/enhancer display precocious lobuloalveolar
development and differentiation in the mammary glands of vir-
gin mice [30]. Conversely, overexpression of Axin, a negative
regulator of β-catenin, results in defects in lobuloalveolar
development during pregnancy [31]. This is similar to studies
demonstrating that interference of TGF-β signalling during
mammary development induces precocious alveolar differenti-
ation in mice, while targeted overexpression of active TGF-β1
inhibits alveolar development and lactation [2].
In addition to the mammary gland phenotypes, downstream
signalling targets point toward opposing roles for TGF-β and
Wnt/β-catenin pathways. Proteins shown to be upregulated
by the Wnt/β-catenin pathway, such as c-myc, cyclin-D1 and
Id, are usually downregulated by the TGF-β pathway [32-34].
Moreover, studies in other model systems provide direct evi-
dence that the TGF-β pathway can suppress the Wnt/β-cat-
enin pathway [35-37]. For example, bone morphogenic
protein-2 (BMP-2), a TGF-β family member, can inhibit Wnt
signalling in osteoblast progenitors via a Smad1/Dvl interac-
tion [38] and, additionally, TGF-β signalling can dictate the
size of the dorsal midbrain by antagonising canonical Wnt sig-
nalling and negatively regulating self-renewal of neuroepithe-
lial stem cells [36]. Together with results presented here there
is strong evidence for antagonistic interactions between TGF-
β and Wnt/β-catenin pathways in the mammary gland.
Despite significant evidence in favour of antagonism between
TGF-β and Wnt/β-catenin signalling, other studies suggest
that these two pathways act together [39]. The extent of coop-
eration ranges from similar mutant phenotypes between β-cat-
enin and Smad2/4 during gastrulation, the necessity of TGF-
β/Smad in mediating β-catenin responses such as epithelial
mesenchymal transition and apoptosis, and also the presence
of LEF1 and Smad binding sites in certain promoters. Moreo-
ver, a recent study demonstrated a unique TGF-β/Wnt respon-
sive gene signature in mammary and intestinal cancers [39].
Given the complexity and biphasic nature of TGF-β in mam-
mary tumourigenesis, it is likely that our hypothesis that TGF-β
acts to inhibit Wnt/β-catenin signalling, and the hypotheses of
others that suggest cooperation between TGF-β and Wnt sig-
nalling are not mutually exclusive. Our studies propose that
alterations in TGF-β signalling promote the stabilisation of
intracellular β-catenin, enhancing mammary tumourigenesis,
but the effects of TGF-β on late-stage tumour progression,
such as those associated with epithelial mesenchymal transi-
tion and metastasis, might involve cooperation with Wnt sig-
nalling.
Figure 5
K6 and K14 expressing populations are increased in Wnt5a-/- and DNIIR tumours K6 and K14 expressing populations are increased in Wnt5a-/- and DNIIR tumours. Immunohistochemistry for K6 demonstrating the expansion of this 
progenitor population in (a) MMTV-PyVmT:Wnt5a-/- and (b) MMTV-PyVmT:DNIIR tumours compared with control groups (five per group). Immuno-
histochemistry for K14 in (c) MMTV-PyVmT:Wnt5a-/- and (d) MMTV-PyVmT:DNIIR tumours, along with representative controls (five per group). The 
K14 population in both Wnt5a-/- and DNIIR tumours displays a unique rounded morphology. DNIIR = dominant-negative transforming growth factor-
β type II receptor; K = keratin; MMTV = mouse mammary tumour virus promoter/enhancer; PyVmT = polyoma virus middle T antigen; Wnt = Wing-
less-related protein family.Breast Cancer Research    Vol 11 No 2    Roarty et al.
Page 10 of 11
(page number not for citation purposes)
The heterogeneity of breast cancers has sparked interest in
the presence of a population of cells termed 'cancer stem
cells' or 'tumour-initiating cells' that are small in number, undif-
ferentiated and can give rise to differentiated lineages that
form the bulk of the tumour [40]. The specific initiating onco-
genic pathway present in genetically engineered mouse mod-
els is thought to create distinct pathological features [41,42].
Along with the oncogenic stimulus, studies have demon-
strated that the cell of origin also can dictate pathological fea-
tures observed in tumours. Although MMTV-PyVmT is thought
to transform a more differentiated cell-type in the mammary
gland [23], it has been proposed that activation of Wnt/β-cat-
enin signalling supports the expansion of a progenitor popula-
tion in tumours [29,41,42]. In our model, we demonstrated
that in the context of MMTV-PyVmT, a K6 progenitor popula-
tion and an unusual K14 expressing population were
expanded in the absence of Wnt5a or when TGF-β signalling
was interrupted. The results suggest that TGF-β and Wnt5a
redirect tumour phenotype to form tumours similar to those
formed by excess Wnt/β-catenin signalling. By extension, it is
reasonable to propose that TGF-β and Wnt5a may also regu-
late the stem cell population.
The existence of self-renewing, multipotent cells in the devel-
oping mammary gland has been known for many years [18].
Fragments of mouse mammary epithelium transplanted into a
cleared fat pad can regenerate the entire functional gland.
Subsequent serial transplantation and regeneration of the ini-
tial outgrowths demonstrated the existence of the self-renew-
ing population. Later studies showed that this stem cell
population was enriched for Sca1, which was originally identi-
fied as a marker of haematopoietic cells [28]. It has been sug-
gested that one of the major roles of canonical Wnts in the
skin, intestine and other tissues including the breast is to reg-
ulate maintenance and proliferation of stem cells [43,44].
TGF-β, however, can limit the stem cell population and facili-
tates the differentiation of this population to a more committed
state [45-47]. We propose a model in which TGF-β acting
through Wnt5a limits Wnt/β-catenin signalling and the stem
cell population. Due to controversies regarding stem cell mark-
ers, testing this model will require extensive cell profiling and
functional studies to re-populate cleared fat pads.
In summary, the similarities observed in Wnt5a-/- tumours to
those tumours derived from components of the Wnt/β-catenin
pathway provide the first evidence that Wnt5a acts to inhibit
the Wnt/β-catenin pathway in the mammary gland. The fact
that Wnt5a is regulated by TGF-β provides another interesting
facet that warrants further investigation with respect how
these two factors are linked throughout mammary gland devel-
opment, in the regulation of stem cell dynamics and during
mammary tumourigenesis.
Conclusions
Previously, we showed that Wnt5a is a direct target of TGF-β
signalling and is required for many of the effects of TGF-β in
mammary development. The key findings here are that TGF-β
and Wnt5a antagonise Wnt/β-catenin signalling in mammary
tissue and that loss of TGF-β or Wnt5a signalling can redirect
the phenotype of mammary tumours to that resembling
tumours induced by excessive Wnt/β-catenin. These findings
provide a new mechanism whereby TGF-β could act as a
tumour suppressor.
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